Earlier, the company has received $5m grant from the NMSS in partnership with the NMSS’s Southern California chapter, with support from the National Institutes of Health, and $860,440 in grant funding through the American Recovery and Reinvestment Act.
Adeona Pharma is evaluating 150 patients in the randomized, double-blind, placebo-controlled clinical trial at 15 centers in the US.
University of California Los Angeles (UCLA) Multiple Sclerosis Program, UCLA Department of Neurology director Rhonda Voskuhl said they are very grateful to the NMSS for its continuous support of this MS program, from the preclinical development to the pilot and multi-center clinical trials, and now this current grant funding.
"Their commitment to pursuing estriol for MS could potentially lead to a new, safe and effective oral therapy for this debilitating disease," Voskuhl said.